About 8 results found for searched term "140-40-9" (0.121 seconds)
Cat.No. | Name | Target |
---|---|---|
M5816 | Nithiamide | Antibiotic |
CL 5279; Aminitrozole | ||
Nithiamide is a non-5-nitroimidazole compound. | ||
M13620 | CCT244747 | Checkpoint |
CCT244747 is a potent, orally bioavailable and highly selective CHK1 inhibitor, with an IC50 of 7.7 nM; CCT244747 also abrogates G2 checkpoint with an IC50 of 29 nM. | ||
M13796 | NucPE1 | Fluorescent Dye |
Nuclear Peroxy Emerald 1 | ||
NucPE1 (Nuclear Peroxy Emerald 1) is a nuclear-localized fluorescent hydrogen peroxide that is specifically localized to cellular nuclei without appended targeting moieties. | ||
M10546 | Indophagolin | Autophagy |
Indophagolin is a potent, indoline-containing autophagy inhibitor (IC50=140 nM). Indophagolin antagonizes the purinergic receptor P2X4 as well as P2X1 and P2X3 with IC50s of 2.71, 2.40 and 3.49 μM, respectively. | ||
M30403 | Pomaglumetad methionil hydrochloride | GluR |
LY2140023 hydrochloride | ||
Pomaglumetad methionil hydrochloride (LY2140023 hydrochloride) is an orally active, methionine precursor of the selective mGlu2/3 receptor agonist LY404039. Pomaglumetad methionil hydrochloride has the potential for schizophrenia research. | ||
M30404 | Pomaglumetad methionil anhydrous | GluR |
LY2140023 | ||
Pomaglumetad methionil anhydrous (LY2140023) is an orally active, methionine precursor of the selective mGlu2/3 receptor agonist LY404039. LY2140023 has the potential for schizophrenia research. | ||
M30972 | Pomaglumetad methionil | GluR |
LY2140023 hydrate | ||
Pomaglumetad methionil (LY2140023 hydrate) is an oral methionine precursor of the potent specific mGlu2/3 receptor agonist LY404039. Pomaglumetad methionil is well-tolerated and has a distinct safety profile, and can be used for schizophrenia. | ||
M53909 | TC14012 | CXCR |
TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.